Sign in to follow
Search Results

0 results for 'Wachtell, Lipton, Rosen & Katz'

You can use to get even better search results
April 27, 2015 |

Am Law 100 Analysis: The Superrich Firms Pull Away

It was a year of solid gains for The Am Law 100, especially for a burgeoning group of top firms.
14 minute read
April 27, 2015 | Law.com

From the Editor: The Am Laws at 30

You're not getting older, you're getting better.
2 minute read
April 27, 2015 | Law.com

The Am Law 100: Introducing Our New Profits Metric

To help add context to our reporting on law firm profits, this year's Am Law 100 report adds a new metric, profits per lawyer.
13 minute read
April 27, 2015 | Law.com

Am Law 100 Analysis: The Superrich Firms Pull Away

It was a year of solid gains for The Am Law 100, especially for a burgeoning group of top firms.
14 minute read
April 25, 2015 |

Top Activist Lawyer Lands on a New Team

Morgan Stanley has hired Schulte Roth & Zabel's David Rosewater, co-head of the firm's global shareholder activism practice, to lead its activist defense group. But Rosewater, who previously worked at Cravath, Swaine & Moore, won't be fighting Marty Lipton's war.
6 minute read
April 25, 2015 | Law.com

Top Activist Lawyer Lands on a New Team

Morgan Stanley has hired Schulte Roth & Zabel's David Rosewater, co-head of the firm's global shareholder activism practice, to lead its activist defense group. But Rosewater, who previously worked at Cravath, Swaine & Moore, won't be fighting Marty Lipton's war.
6 minute read
April 24, 2015 |

Litigation Department of the Year, Securities: Kirkland & Ellis

With help from Kirkland litigators, Pershing Square's push for an Allergan takeover worked out to the tune of $2.2 billion.
4 minute read
April 24, 2015 | Law.com

Litigation Department of the Year, Securities: Kirkland & Ellis

With help from Kirkland litigators, Pershing Square's push for an Allergan takeover worked out to the tune of $2.2 billion.
4 minute read
April 23, 2015 |

Deal Watch: Big Firm Pharma Deal Flow Continues With Teva's Mylan Bid

Big Pharma leads the list of billion-dollar deals this week with a $40 billion, unsolicited bid made by Israel's Teva Pharmaceutical Industries Ltd. for fellow generic-drug maker Mylan N.V.
5 minute read
April 23, 2015 | Law.com

Deal Watch: Big Firm Pharma Deal Flow Continues With Teva's Mylan Bid

Big Pharma leads the list of billion-dollar deals this week with a $40 billion, unsolicited bid made by Israel's Teva Pharmaceutical Industries Ltd. for fellow generic-drug maker Mylan N.V.
5 minute read

TRENDING STORIES

    More from ALM

    More from ALM

    Legal Speak is a weekly podcast that makes sense of what’s happening in the legal industry.

    Resources